National Academies Press: OpenBook

Challenges for the FDA: The Future of Drug Safety: Workshop Summary (2007)

Chapter: Appendix A Workshop Agenda

« Previous: References
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

Appendix A
Workshop Agenda

Symposium on the Future of Drug Safety: Challenges for FDA

March 12, 2007

Hotel Monaco, Paris Ballroom

700 F Street NW, Washington, DC


Symposium Objective: The Institute of Medicine recently released a report, The Future of Drug Safety: Promoting and Protecting the Health of the Public. This report includes recommendations for improving the U.S. drug safety system. These recommendations would likely entail significant new commitments for an agency that some consider to be financially strained by existing responsibilities. The meeting will consider the types and magnitudes of resources needed to achieve the goals of the IOM report. It will focus on a subset of IOM recommendations (attached) which were deemed to have significant resource implications—these are grouped into five topic areas: increased FDA funding; integration of pre- and postmarket review; enhancing postmarket safety monitoring; conducting confirmatory drug safety and efficacy studies; and enhancing postmarket regulation and enforcement. The complete list of recommendations can be found in the report or the executive summary at http://www.nap.edu/catalog/11750.html. For each topic, presenters will describe the relevant IOM recommendations, the FDA’s current capacities and initiatives; and the resource implications of those recommendations. Perspectives will include FDA officials (for information on current operations and plans), industry, patient advocates, and other experts.

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

7:30 am

Coffee/Refreshments

8:00 am

Welcome

 

GAIL CASSELL, SYMPOSIUM CHAIR AND MODERATOR

Co-Chair, Forum on Drug Discovery, Development, and Translation

Vice President, Scientific Affairs and Distinguished Lilly

Research Scholar for Infectious Diseases

Eli Lilly and Company


Session 1: Preserving the Public Trust: Ensuring Drug Safety, Efficacy, and Availability


Session Objectives: The IOM drug safety report recommended that the FDA receive “substantially increased resources” to support improvements in the system for ensuring drug safety and efficacy (Recommendation 7.1). This session will provide an overview of the role of the FDA in protecting the public, and the magnitude of resources appropriate to the task, from the perspectives of a former Secretary of Health and Human Services, a former FDA Commissioner, and an advocate for patients. In addition, the FDA’s official response to the IOM recommendations will be presented.

8:10 am

Ensuring commitment to safety through a strong FDA.

 

TOMMY THOMPSON

Honorary Chairman

Coalition for a Stronger FDA

Former Secretary for Health, U.S. Department of Health and

Human Services

8:20 am

Reflections on the historical challenges of regulating drug safety and efficacy.

 

JANE HENNEY

Senior Vice President and Provost for Health Affairs

University of Cincinnati Academic Health Center

Former Commissioner of Food and Drugs, U.S. Food and Drug Administration

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

8:30 am

Preserving public trust in the drug safety regulatory system.

 

ELLEN SIGAL

Chairperson

Friends of Cancer Research

8:40 am

The FDA response to the IOM drug safety report.

 

STEVE GALSON

Member, Forum on Drug Discovery, Development, and Translation

Director, Center for Drug Evaluation and Research

U.S. Food and Drug Administration

8:50 am

Q & A


Session 2: Integration of Pre- and Postmarket Review


Session Objectives: The IOM Drug Safety report recommends adoption of a lifecycle approach to drug review, including integration of pre- and postmarket review (Recommendations 3.4, 4.4, 4.5, 4.13, and 5.4). This session will describe the FDA’s drug review process, the IOM recommendations for implementing a lifecycle approach to drug safety review, and the levels and types of resources needed to address the IOM report goals. In addition, the session will consider approaches to strengthening the scientific basis of premarket review.

9:05 am

Overview of key IOM recommendations and introductions.

 

ALTA CHARO, PANEL MODERATOR

Member, IOM Drug Safety Committee

Professor

University of Wisconsin

Panel: Each panelist will make brief remarks followed by a Q&A period at the conclusion of the presentations.

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

9:15 am

Operational challenges for instituting a lifecycle approach to drug review.

 

HUGH TILSON

Clinical Professor, Public Health Leadership

University of North Carolina School of Public Health

9:25 am

Building FDA’s capacity for science-based premarket review.

 

GARRET FITZGERALD

Member, Forum on Drug Discovery, Development, and Translation

Professor of Medicine, Professor and Chair of Pharmacology, Department of Pharmacology

University of Pennsylvania School of Medicine

9:35 am

Current FDA initiatives to integrate pre- and postmarket review.

 

BOB TEMPLE

Director, Office of Drug Evaluation

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

 

ELLIS UNGER

Deputy Director for Science (Acting)

Office of Surveillance and Epidemiology

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

9:55 am

Industry’s role in the institution of a lifecycle approach to drug safety review.

 

TIM FRANSON

Vice President, Global Regulatory Affairs

Lilly Research Laboratories

Eli Lilly and Company

10:05 am

Q & A

10:35 am

Break

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

Session 3: Enhancing Postmarket Safety Monitoring


Session Objectives: The IOM drug safety report recommends significant changes in the FDA’s postmarket review process (Recommendations 4.1, 4.2, and 4.6). This session will describe the FDA’s current initiatives and the IOM recommendations for improving postmarket monitoring and drug safety review, and discuss the resources required to achieve the goals of the IOM report. Presentations will also consider ways to leverage existing resources to enhance postmarket safety monitoring, including the innovative use of databases and resources from other agencies, health plans, and industry.

10:50 am

Overview of key IOM recommendations and introductions.

 

ANDY STERGACHIS, PANEL MODERATOR

Member, IOM Drug Safety Committee

Professor of Epidemiology and Adjunct Professor of Pharmacy

University of Washington

Panel: Each panelist will make brief remarks followed by a Q&A period at the conclusion of the presentations.

11:00 am

FDA initiatives for improving drug safety monitoring.

 

GERALD DAL PAN

Director, Office of Surveillance and Epidemiology

Center for Drug Evaluation and Research

U.S. Food and Drug Administration

11:10 am

Innovative use of existing data bases to aid in drug safety monitoring.

 

MARK MCCLELLAN

Visiting Senior Fellow

AEI Brookings Joint Center for Regulatory Studies

Former Commissioner of Food and Drugs, U.S. Food and Drug Administration

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

11:20 am

Mining health plan patient data for drug safety monitoring.

 

RICHARD PLATT

Professor and Chair

Harvard Medical School and Harvard Pilgrim Health Care

11:30 am

Leveraging non-FDA resources for drug safety surveillance.

 

BARBARA ALVING

Acting Director, National Center for Research Resources

National Institutes of Health

11:40 am

Feasibility of implementing new approaches to enhance postmarket safety monitoring.

 

ALEC WALKER

Senior Vice President for Epidemiology

i3 Drug Safety, Ingenix

11:50 am

Industry initiatives for utilizing health care data.

 

RON KRALL

Member, Forum on Drug Discovery, Development, and Translation

Senior Vice President and Chief Medical Officer

GlaxoSmithKline

12:00 pm

Q & A

12:30 pm

Lunch/Roundtable Discussion


Session 4: Conducting Confirmatory Drug Safety and Efficacy Studies


Session Objectives: The FDA is limited in its ability to conduct studies on drugs that are already approved to assess the safety concerns or efficacy of drugs in clinical use. The IOM drug safety report calls for the development of public–private partnerships to prioritize, plan, and fund confirmatory drug safety and efficacy studies (Recommendation 4.3). Panelists will discuss the FDA’s current capacity to organize such studies, consider approaches to expanding this capacity, and examine the costs of

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

implementing these approaches. In addition, the IOM recommendation calling for enhanced clinical trial registration will be discussed (Recommendation 4.11).

1:30 pm

Overview of key IOM recommendations and introductions.

 

ANDY STERGACHIS, PANEL MODERATOR

Panel: Each panelist will make brief remarks followed by a Q&A period at the conclusion of the presentations.

1:40 pm

Current FDA initiatives to expand research capabilities.

 

JANET WOODCOCK

Member, Forum on Drug Discovery, Development, and Translation

Deputy Commissioner for Operations and Chief Medical Officer

U.S. Food and Drug Administration

1:50 pm

Funding large research studies.

 

ROBERT CALIFF

Member, Forum on Drug Discovery, Development, and Translation

Director, Duke Translational Medicine Institute

Professor of Medicine

Vice Chancellor for Clinical and Translational Research

Duke University Medical Center

2:00 pm

Enhancing the value of clinical trial registration.

 

DEBORAH ZARIN

Director, ClinicalTrials.gov

National Library of Medicine

2:10 pm

An industry perspective on expanding the capacity for postmarket studies and regulation of ClinicalTrials.gov.

 

GRETCHEN DIECK

Senior Vice President, Safety and Risk Management

Pfizer Inc

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

2:20 pm

Q & A

2:50 pm

Break


Session 5: Enhancing Postmarket Regulation and Enforcement


Session Objectives: The IOM report calls for clarification or strengthening of existing authority to regulate drugs already on the market, new methods to address direct-to-consumer advertising, and sufficient enforcement tools to ensure that regulatory requirements imposed at or after approval are fulfilled (Recommendations 5.1, 5.2, and 5.3). This session will describe how the FDA currently deals with concerns about drugs that are on the market, will consider various approaches to enhancing the FDA’s ability to regulate drugs following approval, and will examine the resource implications for both the FDA and industry of alternative approaches.

3:05 pm

Overview of key IOM recommendations and introductions.

 

ALTA CHARO, PANEL MODERATOR

Panel: Each panelist will make brief remarks followed by a Q&A period at the conclusion of the presentations.

3:15 pm

Providing FDA with clear and unambiguous regulatory authority.

 

CHRIS SCHROEDER

Member, IOM Drug Safety Committee

Professor of Law and Public Policy Studies

Duke University School of Law

3:25 pm

Effective use of existing FDA authorities.

 

PETER BARTON HUTT

Senior Counsel

Covington & Burling LLP

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

3:35 pm

Anticipated impact of new regulations upon patient safety and access.

 

EVE E. SLATER

Director

Vertex Pharmaceuticals and Theravance, Inc.

Former Assistant Secretary for Health, U.S. Department of Health and Human Services

3:45 pm

Making resources for postmarket compliance a priority.

 

MARY PENDERGAST

President

Pendergast Consulting

3:55 pm

Industry perspectives on enhanced regulatory authority.

 

MARLENE HAFFNER

Executive Director, Global Regulatory and Intelligence Policy

Amgen, Inc.

4:05 pm

Q & A


Session 6: Drug Safety Regulation: Looking to the Future


Session Objectives: Panelists will reflect on the challenges and opportunities for enhancing drug safety discussed throughout the day, and share their thoughts on the steps necessary to ensure the continued ability of the FDA to meet the challenge.

4:40 pm

MYRL WEINBERG

President

National Health Council

4:50 pm

MARK MCCLELLAN

5:10 pm

Q & A

Closing Remarks

5:20 pm

GAIL CASSELL, SYMPOSIUM CHAIR

5:30 pm

Adjourn

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

Selected Recommendations from the IOM Report The Future of Drug Safety, Referred to in the Symposium1

Session 1: Preserving the Public Trust: Ensuring Drug Safety, Efficacy, and Availability


7.1: To support improvements in drug safety and efficacy activities over a product’s lifecycle, the committee recommends that the Administration should request and Congress should approve substantially increased resources in both funds and personnel for the Food and Drug Administration.


Session 2: Integration of Pre- and Postmarket Review


3.4: The committee recommends that CDER [Center for Drug Evaluation and Research] appoint an OSE [Office of Surveillance and Epidemiology] staff member to each New Drug Application review team and assign joint authority to OND [Office of New Drugs] and OSE for postapproval regulatory actions related to safety.


4.4: The committee recommends that CDER assure the performance of timely and scientifically-valid evaluations (whether done internally or by industry sponsors) of Risk Minimization Action Plans (RiskMAPs).


4.5: The committee recommends that CDER develop and continually improve a systematic approach to risk-benefit analysis for use throughout the FDA in the preapproval and postapproval settings.


4.13: The committee recommends that the CDER review teams regularly and systematically analyze all postmarket study results and make public their assessment of the significance of the results with regard to the integration of risk and benefit information.


5.4: The committee recommends that FDA evaluate all new data on new molecular entities no later than 5 years after approval. Sponsors will submit a report of accumulated data relevant to drug safety and efficacy, including any additional data published in a peer-reviewed journal, and will report on the status of any applicable conditions imposed on the distribution of the drug called for at or after the time of approval.

1

To see all 25 recommendations, refer to the full report or the summary at http://www.nap.edu/catalog/11750.html.

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

Session 3: Enhancing Postmarket Safety Monitoring


4.1: The committee recommends that in order to improve the generation of new safety signals and hypotheses, CDER [Center for Drug Evaluation and Research] (a) conduct a systematic, scientific review of the AERS [Adverse Event Reporting System], (b) identify and implement changes in key factors that could lead to a more efficient system, and (c) systematically implement statistical-surveillance methods on a regular and routine basis for the automated generation of new safety signals.


4.2: The committee recommends that in order to facilitate the formulation and testing of drug safety hypotheses, CDER (a) increase their intramural and extramural programs that access and study data from large automated healthcare databases and (b) include in these programs studies on drug utilization patterns and background incidence rates for adverse events of interest, and (c) develop and implement active surveillance of specific drugs and diseases as needed in a variety of settings.


4.6: The committee recommends that CDER build internal epidemiologic and informatics capacity in order to improve postmarket assessment of drugs.


Session 4: Conducting Confirmatory Drug Safety and Efficacy Studies


4.3: The committee recommends that the Secretary of HHS [Health and Human Services], working with the Secretaries of Veterans Affairs and Defense, develop a public-private partnership with drug sponsors, public and private insurers, for-profit and not-for-profit health care provider organizations, consumer groups, and large pharmaceutical companies to prioritize, plan, and organize funding for confirmatory drug safety and efficacy studies of public health importance. Congress should capitalize the public share of this partnership.


4.11: The committee recommends that Congress require industry sponsors to register in a timely manner at clinicaltrials.gov, at a minimum, all phase 2 through 4 clinical trials, wherever they may have been conducted, if data from the trials are intended to be submitted to the FDA as part of an NDA [New Drug Application], sNDA [supplemental New Drug Application], or to fulfill a postmarket commitment. The committee further recommends that this requirement include the posting of a structured field summary of the efficacy and safety results of the studies.

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×

Session 5: Enhancing Postmarket Regulation and Enforcement


5.1: The committee recommends that Congress ensure that the Food and Drug Administration has the ability to require such postmarketing risk assessment and risk management programs as are needed to monitor and ensure safe use of drug products. These conditions may be imposed both before and after approval of a new drug, new indication, or new dosage, as well as after identification of new contraindications or patterns of adverse events. The limitations imposed should match the specific safety concerns and benefits presented by the drug product. The risk assessment and risk management program may include:

  1. Distribution conditioned on compliance with agency-initiated changes in drug labels.

  2. Distribution conditioned on specific warnings to be incorporated into all promotional materials (including broadcast direct-to-consumer [DTC] advertising).

  3. Distribution conditioned on a moratorium on DTC advertising.

  4. Distribution restricted to certain facilities, pharmacists, or physicians with special training or experience.

  5. Distribution conditioned on the performance of specified medical procedures.

  6. Distribution conditioned on the performance of specified additional clinical trials or other studies.

  7. Distribution conditioned on the maintenance of an active adverse event surveillance system.

5.2: The committee recommends that Congress provide oversight and enact any needed legislation to ensure compliance by both the Food and Drug Administration and drug sponsors with the provisions listed above. FDA needs increased enforcement authority and better enforcement tools directed at drug sponsors, which should include fines, injunctions, and withdrawal of drug approval.


5.3: The committee recommends that Congress amend the Food, Drug and Cosmetic Act to require that product labels carry a special symbol such as the black triangle used in the UK or an equivalent symbol for new drugs, new combinations of active substances, and new systems of delivery of existing drugs. The Food and Drug Administration should restrict direct-to-consumer advertising during the period of time the special symbol is in effect.

Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 81
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 82
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 83
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 84
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 85
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 86
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 87
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 88
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 89
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 90
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 91
Suggested Citation:"Appendix A Workshop Agenda." Institute of Medicine. 2007. Challenges for the FDA: The Future of Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/11969.
×
Page 92
Next: Appendix B Speaker Biographies »
Challenges for the FDA: The Future of Drug Safety: Workshop Summary Get This Book
×
Buy Paperback | $44.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

As the principal agency regulating food, drugs, medical devices, and biological products used by Americans, the U.S. Food and Drug Administration (FDA) serves one of the most critical consumer protection functions of the federal government. The FDA's reach is enormous, regulating products that represent roughly 25 percent of all consumer spending in the United States. Since 1992, however, federal funding for the agency has diminished, and the FDA's Center for Drug Evaluation and Research (CDER) currently relies on the fees it receives from the industry it regulates to fund the majority of its drug regulation functions. Prescription drug safety is receiving heightened press coverage and congressional scrutiny as a result of recent, highly publicized events, such as the recall of Vioxx because of its link to heart attacks, and the link between certain antidepressants (selective serotonin reuptake inhibitors, or SSRIs) and an increased risk of suicidal ideation in children.

To address these concerns, the FDA in 2005 commissioned the Institute of Medicine (IOM) to conduct an independent assessment of the current U.S. drug safety system. In September 2006, the IOM committee released its report—The Future of Drug Safety: Promoting and Protecting the Health of the Public—which included 25 recommendations for improving the system for drug safety review. The committee identified four major vulnerabilities in the U.S. drug safety system: (1) chronic underfunding; (2) organization problems, particularly inadequate integration of pre-and postmarket data review; (3) a range of technical problems related to the insufficient quantity and quality of postmarket data and inadequate capability to systematically monitor the risks and benefits of drugs after marketing; and (4) unclear regulatory authority and insufficiently flexible regulatory tools. Since the IOM report was issued, the FDA has taken a number of steps toward implementing the recommended improvements. Like many government agencies, however, the FDA is financially strained by its existing responsibilities, and fully implementing the recommended improvements to the drug safety system would require significant financial commitments.The IOM report addressed some of the costs associated with its recommendations, but left many unanswered questions about the resources required to fully achieve the envisioned improvements. To better understand the types and magnitude of resources required to achieve the goals of the IOM report, the IOM's Forum on Drug Discovery, Development, and Translation convened a 1-day symposium in March 2007.
Challenges for the FDA: The Future of Drug Safety, Workshop Summary explains the presentations and discussions in seven key areas: addressing the FDA's resource challenges; strengthening the scientific base of the agency; integrating pre- and postmarket review; enhancing postmarket safety monitoring; conducting confirmatory drug safety and efficacy studies; enhancing the value of clinical trial registration; and enhancing the FDA's postmarket regulation and enforcement.
  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!